Which has the lower trailing P/E, CAI or HQY?

HQY has the lower trailing P/E: CAI trades at 78.36 and HQY at 32.86. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, CAI or HQY?

Over the past five years, CAI grew revenue faster — CAI at a 26.15% CAGR versus HQY at 12.96%.

Is CAI or HQY more profitable?

HQY runs the higher net margin — CAI at 10.62% versus HQY at 17.36%.

Caris Life Sciences, Inc. (CAI) vs HealthEquity, Inc. (HQY)

A side-by-side comparison of Caris Life Sciences, Inc. and HealthEquity, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CAI

Caris Life Sciences, Inc.

$7.93B

$28.05HealthcareDelayed quote: Oct 6, 2026, 2:00 PM EDT

HQY

HealthEquity, Inc.

$7.61B

$91.02HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT

Total return — CAI vs HQY

growth of $100 · dividends reinvested · last 1y

CAI +8.5% (+8.5%/yr)HQY -8.5% (-8.5%/yr)CAI compounded faster over this window

CAI HQY

CAI vs HQY: by the numbers

•CAI is the larger company ($7.93B vs $7.61B market cap).
•HQY trades at the lower trailing earnings multiple (32.86 vs 78.36 P/E), one valuation lens rather than an overall verdict.
•HQY converts more revenue to profit (17.36% vs 10.62% net margin).
•CAI grew revenue faster over the past five years (26.15% vs 12.96% CAGR).

Metrics side by side

Valuation

Metric	CAI	HQY
P/E ratio	78.36	32.86
Forward P/E	241.70	19.27
PEG ratio	N/A	0.40
P/S ratio	8.01	5.59
P/B ratio	13.40	3.82
EV / EBITDA	44.18	17.31
FCF yield	1.85%	6.20%

Profitability

Metric	CAI	HQY
Gross margin	69.66%	75.21%
Operating margin	5.56%	25.61%
Net margin	10.62%	17.36%
ROE	17.77%	11.88%
ROIC	14.76%	8.55%

Growth (annualized)

Metric	CAI	HQY
Revenue CAGR (5Y)	26.15%	12.96%
EPS CAGR (5Y)	N/A	83.56%
FCF CAGR (5Y)	N/A	36.72%
Total return CAGR (5Y)	N/A	7.00%

Frequently asked

Which has the lower trailing P/E, CAI or HQY?: HQY has the lower trailing P/E: CAI trades at 78.36 and HQY at 32.86. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, CAI or HQY?: Over the past five years, CAI grew revenue faster — CAI at a 26.15% CAGR versus HQY at 12.96%.
Is CAI or HQY more profitable?: HQY runs the higher net margin — CAI at 10.62% versus HQY at 17.36%.

Go deeper

Full CAI analysis Full HQY analysis Interactive comparison tool

Dig into the metrics

Caris Life Sciences P/E ratio HealthEquity P/E ratio Caris Life Sciences ROE HealthEquity ROE Caris Life Sciences operating margin HealthEquity operating margin Caris Life Sciences revenue growth HealthEquity revenue growth Caris Life Sciences free cash flow HealthEquity free cash flow

Caris Life Sciences & HealthEquity appear in these rankings

Fastest Revenue Growth Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.